The European Union is preparing the biggest overhaul of its pharmaceutical framework in two decades, and medical cannabis is squarely in the frame. The political agreement reached in December 2025 and voted through Parliament in March 2026 is heading for final adoption this summer, with a two-year transition that will make the new system fully operational by around 2028.
What the Pharmaceutical Package changes
The reform replaces the architecture set by Directive 2001/83/EC and Regulation 726/2004, the basis on which medicines have been authorised in Europe for twenty years. For the cannabis sector, two provisions stand out. The first is a new breakthrough orphan designation, offering 11 years of market exclusivity —up from 9 under the standard orphan pathway— for treatments targeting rare diseases with no authorised alternative.
The second is a regulatory sandbox: a mechanism that lets the Commission design bespoke frameworks for medicines that do not fit conventional requirements, especially where classic clinical trials are unfeasible. On top of that, a 180-day deadline for the EMA’s CHMP to issue an opinion on valid applications marks a notable acceleration versus historical timelines.
Tougher manufacturing rules
The tightening is not merely theoretical. Since 15 January 2026, Commission Delegated Regulation (EU) 2024/1701 has applied, introducing new post-authorisation variation categories, reinforcing chemistry, manufacturing and controls (CMC) documentation, and revising stability data requirements. In practice, any EU-GMP certified operator aiming to market across several countries will have to raise its documentary compliance.
A market driving the reform
The context explains the urgency. Germany imported more than 50 tonnes of medical cannabis in the first quarter of 2026 alone and accounts for much of the value of European imports. Analysts place the European market between EUR 2 billion and EUR 4 billion by 2028, driven by Germany, the UK private sector and the roll-out of France’s programme. Capital, meanwhile, has shifted to a profitability mandate: investment now flows toward EU-GMP cultivation and manufacturing infrastructure, distribution and compliance services, no longer toward growth at any cost.
- Market access: the mutual recognition route becomes more attractive for scaling across countries.
- Barrier to entry: the new CMC requirements reward those with mature EU-GMP processes.
- Exclusivity window: the 11 years for rare diseases open a genuine R&D incentive.
- Planning: with full effect by 2028, it pays to order registrations and dossiers now.
Today only Sativex and Epidyolex hold EU marketing authorisation, but companies such as Vertanical expect to launch product in 2026 leaning on mutual recognition. The reform does not remove the demands: it clarifies them and, in some stretches, tightens them.
Why it matters for your business
For growers, laboratories, distributors and investors, the message is clear: the European framework is professionalising and rewards rigorous compliance over improvisation. Understanding these changes before 2028 is a competitive advantage, not a formality.
These are exactly the debates we will tackle at Spannabis B2B Bilbao 2027, on 11 March at the VIP Room of the BEC: regulation, market access and investment strategy with the companies defining the sector. Secure your place through tickets or request your B2B table to meet the players shaping medical cannabis in Europe.
Sources: Business of Cannabis and the European Union Drugs Agency (EUDA).